TScan Therapeutics Announces Launch of Proposed Public Offering
May 25, 2023 16:06 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors
May 24, 2023 16:13 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) (TScan), a clinical-stage biopharmaceutical company focused on the development of T cell receptor...
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 17, 2023 07:00 ET
|
TScan Therapeutics, Inc.
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation Company to host a virtual KOL event featuring Monzr M. Al Malki, M.D., to...
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 07:00 ET
|
TScan Therapeutics, Inc.
Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study;...
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
May 09, 2023 09:00 ET
|
TScan Therapeutics, Inc.
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With...
TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 02, 2023 16:42 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors
April 10, 2023 07:00 ET
|
TScan Therapeutics, Inc.
Deepens the Board’s clinical oncology and commercialization expertise as programs for hematologic malignancies and solid tumors advance Company also announces key leadership promotions WALTHAM,...
TScan Therapeutics Announces CEO Transition
March 31, 2023 08:00 ET
|
TScan Therapeutics, Inc.
David Southwell steps down; Gavin MacBeath, Ph.D., Chief Scientific and Operating Officer, to serve as acting CEO Company reaffirms previously disclosed milestones and cash runway; provides clinical...
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 14, 2023 07:00 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
March 13, 2023 16:05 ET
|
TScan Therapeutics, Inc.
WALTHAM, Mass., March 13, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered...